Precision Genome Editing: The Synergy of CRISPR and Nanotechnology in Cancer Treatment

Abstract

In recent years, the applications of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology have revolutionized genetics and molecular biology. It has expanded beyond genetic editing to include innovative cancer treatment and nanotechnology approaches as a ground-breaking genome editing tool. It has emerged as a potent tool in the battle against cancer. By targeting and modifying specific genes associated with tumor development and growth, CRISPR offers a precise means of combating this devastating disease. Researchers are increasingly utilizing CRISPR to enhance cancer therapies, from boosting the efficacy of traditional treatments to developing novel immunotherapies. Simultaneously, nanotechnology, on the other hand, has opened up new avenues in diagnosing and treating cancer. Due to their unique physical properties, nanoparticles can be engineered for targeted drug delivery and imaging and even be used as vehicles for gene-editing tools like CRISPR. These nanoparticles can navigate the intricate biological environment, homing in on cancer cells while minimizing collateral damage to healthy tissue. This precision is essential in reducing side effects and enhancing the therapeutic potential of anticancer agents. In this review, we emphasize the synergistic potential of CRISPR and nanotechnology, particularly in cancer treatment, highlighting their valuable role in advancing immunotherapy approaches. This nanotechnological perspective contributes significantly to the evolving landscape of research in this field